Hepatocellular carcinoma (HCC) has the second highest cancer-related mortality worldwide ([@bib18]), reflecting its rising incidence, late-stage presentation and limited therapeutic options. Globally, HCC most commonly arises in individuals with underlying chronic liver diseases (CLDs) caused by hepatitis B virus (HBV) or hepatitis C virus. In the UK, where the prevalence of these infections is relatively low, HCC was the ninth commonest cause of cancer mortality in 2014, accounting for 5091 deaths ([@bib3]). Of growing concern, although deaths from other cancers are falling in the UK, HCC-related mortality is rising, having doubled over the last decade. The reasons include a worrying rise in alcohol-related liver disease (ARLD) ([@bib34]), but also a dramatic increase in the prevalence of obesity and type 2 diabetes mellitus-related non-alcoholic fatty liver (NAFLD) ([@bib11]). Driven by stage, potentially curative treatments (resection, transplantation and ablation) are offered to \<15% of patients with HCC. Although first-line palliative locoregional therapy and the multikinase inhibitor sorafenib ([@bib23]) are increasingly used, owing to impaired liver function or deteriorating performance status (PST), up to 50% of those affected are offered supportive care only and overall survival is poor ([@bib11]). The recent failures of targeted second line agents in phase III trials offer limited hope for change, the lack of progress being attributed to a failure to identify the key drivers of hepatocarcinogenesis, as well as the lack of biomarkers guiding stratification of therapy ([@bib24]).

Molecular aberrations in the tumour cells are undoubtedly oncogenic drivers in HCC ([@bib16]; [@bib26]; [@bib27]; [@bib32]; [@bib37]), but interactions with inflammatory cells within the tumour microenvironment may also be key ([@bib14]). Inflammation is a cardinal feature of progressive liver disease and predisposition to HCC, the latter attributed in part to inflammatory cell generated oxidative stress and DNA damage. In addition, however, an inflammatory response associated with a cancer can either aid its elimination or drive its progression. The presence of tumour-infiltrating lymphocytes in HCC resections is associated with better survival ([@bib7]), although cumulative evidence from murine and human studies recognises a balance between the pro-tumour *vs* antitumour effects of different lymphocyte subsets, including regulatory CD4 and cytotoxic CD8 lymphocytes ([@bib13]). Similarly, for other immune cells, such as macrophages and neutrophils, recognition of pro-tumour and anti-tumour subtypes ([@bib15]) and the role of platelets is growing ([@bib4]). The present therapeutic focus is on immune checkpoint inhibitors, a class of drugs which promotes the CD8 anti-tumour response. Although Phase III studies in patients with HCC are awaited, data from early phase trials suggests that this approach may offer a significant survival advantage for some patients ([@bib20]). How to identify patients that will respond to checkpoint inhibition is as yet unknown and the lack of routine diagnostic biopsy for HCC -- owing to good diagnostic performance of contrast enhanced cross sectional imaging combined with the small risks of haemorrhage and tumour seeding in patients with cirrhosis ([@bib28]) -- hampers the development of clinically relevant biomarkers ([@bib30]) for these and other therapies. Monitoring tumour responses can also be challenging.

Given the difficulties acquiring liver tissues, circulating biomarkers that accurately reflect the tumour microenvironment are needed and in parallel to the research focused on the localised tumour immune response, a number of studies exploring circulating inflammatory biomarkers -- which potentially have prognostic or clinically relevant predictive value -- have been reported in patients with HCC. Largely restricted to smaller studies in treatment subgroups, most often in patients with underlying viral hepatitis, an elevated neutrophil to lymphocyte ratio (NLR), reflecting either increases in neutrophils or reduced lymphocytes ([@bib36]), reportedly has prognostic value post resection ([@bib12]), liver transplantation ([@bib21]) and ablation ([@bib9]). Recently the Systemic Immune-Inflammation Index (SII) score -- based on numbers of neutrophils, lymphocytes and platelets ([@bib17]) -- has been proposed as an alternative.

We have interrogated peripheral inflammatory cell counts in two large patient cohorts (583 and 585 patients), wanting to explore the relative biological contributions of neutrophils, lymphocytes and platelets in a more comprehensive fashion -- across all HCC stages, underlying aetiologies and treatment subsets. Searching for driving influences, our aim was to further understand their associations with HCC progression.

Materials and methods
=====================

Patient cohorts
---------------

We have assessed standard blood count data in two patient cohorts. Cohort 1 included patients previously described ([@bib11]). Briefly, these were consecutive patients managed by the Newcastle HCC multidisciplinary meeting between the years 2000 and 2010, guided by internationally accepted guidelines ([@bib2]), including the Barcelona Clinic for Liver Cancer (BCLC) staging algorithm ([@bib22]; [@bib1]). Tumour node metastasis (TNM), Childs-Pugh (CP) and BCLC stages were documented, as were demographic and clinical parameters, Eastern Cooperative Oncology Group (ECOG) PST, treatments and survival. The study was registered with the hospital trust audit department and cases were followed until 31 March 2017, defining a minimum period of 6 years post diagnosis. Blood cell counts, including platelets, neutrophils and lymphocyte data at the time of diagnosis and staging were obtained retrospectively from patients' electronic records. Of 632 consecutive patients with HCC, 49 cases were excluded as complete full blood count data were unavailable, leaving 583 included Newcastle patients. The SII index was calculated as SII=*P × N/L*, where *P*, *N* and *L* were the peripheral platelet, neutrophil and lymphocyte counts, respectively ([@bib17]).

The Newcastle patient data set was used as the exploratory cohort, investigating relationships between circulating immune cells and scores with clinical parameters and outcomes. A second cohort of consecutive HCC patients (*n*=585) was used for validation purposes. The cohort consisted of HCC patients presenting to the Prince of Wales Hospital in Hong Kong between 1 July 2007 and 31 July 2013 ([@bib6], [@bib5]), also followed until 31 March 2017. The construction of this cohort was approved by the Joint Chinese University of Hong Kong -- New Territories East Cluster Research Ethics Committee.

Statistical analyses
--------------------

All statistical analyses were done with SPSS for Windows, version 22 (SPSS Inc., Chicago, IL, USA), licensed to Newcastle University. Figures were drawn using GraphPad Prism 6 (GraphPad Inc., La Jolla, CA, USA). Differences between categorical variables were assessed by Pearson's *χ*^2^-test. Differences between groups of continuous variables that were non-parametrically distributed were assessed using Mann--Whitney or Kruskal--Wallis tests. Bivariate correlations were evaluated using Spearman's rank correlation coefficient. For categorical data, multinomial regression was used to assess the independent associations of multiple variables. A *P*-value of \<0.05 was considered significant. Survival was recorded as months from diagnosis to 31 March 2017. Differences in cumulative survival were determined using the Kaplan--Meier method and a log-rank test. The Cox proportional hazards regression model was used to identify parameters associated with survival. Factors initially considered by univariate analysis included age, gender, associated aetiology, presence cirrhosis, number of tumours, size of largest tumour, presence of extrahepatic disease or portal vein invasion/thrombosis, presence of ascites or encephalopathy, serum *α*-fetoprotein (AFP), serum albumin, serum bilirubin, prothrombin time, whole blood count platelets, neutrophils, lymphocytes, as well as the presence of constitutional symptoms. A cutoff of *P*\<0.05 was used to select variables entered into the multivariate model.

Results
=======

Differences and similarities between the Newcastle and Hong Kong cohorts
------------------------------------------------------------------------

The demographics of the Newcastle and Hong Kong cohorts of patients with HCC are compared and contrasted in [Table 1](#tbl1){ref-type="table"}, alongside the combined cohort of 1168 patients. Similar numbers of patients were studied, but in Newcastle these reflected patients presenting over an 11 year period, compared with 5.5 years in Hong Kong. The Newcastle cohort median age was significantly greater, at 69 *vs* 60 years, and included more women. In addition, there were striking differences in underlying liver disease aetiology, with the majority of HCC arising on a background of fatty liver disease in the Newcastle cohort, *vs* HBV in the Hong Kong cohort. A greater proportion of Newcastle patients had no evidence of underlying CLD of any kind. Despite this, a greater number of Hong Kong patients developed HCC in the absence of cirrhosis -- as is commonly recognised in the presence of chronic HBV infection. Notably, the average tumour size and TNM stage were more advanced in the Hong Kong cohort. While a greater proportion in Hong Kong had extrahepatic disease and portal vein invasion, which contribute to stage BCLC C/D classifications -- a greater proportion of Newcastle patients were classed as BCLC stage D, reflecting more Newcastle cases staged as ECOG PST 3 or 4 and/or liver function CP C. Peripheral blood cell count data is also summarised in [Table 1](#tbl1){ref-type="table"}. Although there were no differences in mean neutrophil or platelet counts, the mean lymphocyte count in the Hong Kong Cohort was slightly but significantly lower than the Newcastle cohort, with consequently higher NLR and SII. The primary surgical treatment in Newcastle was orthotopic liver transplantation, whereas in Hong Kong Prince of Wales Hospital it was resection. Newcastle patients with intermediate stage disease were more likely to receive loco-regional therapy, compared with Sorafenib in the Hong Kong cohort -- reflecting the greater numbers in Hong Kong with extrahepatic disease/TNM IV at presentation, but also the temporal differences in the cohorts and the availability of Sorafenib at the time of patient presentation.

Consequent to the mostly advanced stages at presentation as well as limited therapeutic options as previously described, irrespective of the centre and cohort differences, very similar numbers of patients (41% and 38%, respectively) received supportive care only. Despite the differences between the cohorts, this similarity was possibly the most telling, as there was no significant survival difference between the two. Median survival in the Newcastle cohort was 11.9 months compared with 8.4 months in Hong Kong (Kaplan--Meier, *P*=0.219).

Neutrophils and platelets rise with advanced tumour stage, whereas lymphocytes fall
-----------------------------------------------------------------------------------

In both the Newcastle and Hong Kong cohorts, the NLR and the SII rose in association with advancing TNM, CP and PST, as well as with the BCLC stage, which combines the three. Focusing on the different cell types rather than combination scores, significant incremental increases in median neutrophil count paralleled increases in TNM and PST. Conversely, lymphocytes tended to fall with advancing stages. Platelets fell significantly with advancing CP stage, but increased in association with TNM and BCLC stage. Figures for Newcastle and Hong Kong cohorts independently are shown in [Supplementary Figures 1--4](#sup1){ref-type="supplementary-material"}, whereas the combined cohort data summarising changes with TNM, CP and PST is presented in [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}.

As each of these cell counts can decline in patients with cirrhosis and portal hypertension, which are both drivers of advancing CP and BCLC stage, cirrhosis as a potential confounder was considered. Each of the cell counts, platelets most notably, correlated negatively with the presence of cirrhosis (Spearman's bivariate correlations: neutrophils −0.244, *P*\<0.001; lymphocytes −0.093, *P*=0.001; platelets −0.426, *P*\<0.001). Restricting the assessment of associations of the cell types with the different staging systems to patients without cirrhosis (403 patients), the patterns of change and their significance were similar to those described above (data not shown). The only difference was a lack of a significant association between platelets and CP stage.

The stepwise increases in median neutrophil counts with PST as shown in [Figure 3](#fig3){ref-type="fig"} were interesting and although hard to dissociate from advancing cancer stage, the relationship between neutrophils and PST persisted (*P*\<0.001) in a multinomial regression analysis, which included other factors significantly associated with PST in a univariate analysis (peripheral lymphocyte and platelet counts, but also age, sex, aetiology, cirrhosis, tumour number, tumour size, vascular invasion, extrahepatic disease, ascites, prothrombin time, serum albumin, bilirubin, AFP and Newcastle *vs* Hong Kong cohorts). Data are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}, where variables at each ECOG PST stage were compared with the last and most advanced stage (Stages 3 and 4 combined). Although age, tumour factors (size, vascular invasion and extrahepatic disease) and liver function features (ascites) were significantly associated compared with ECOG PST 0, only falling serum albumin and rising neutrophil count were incrementally and significantly associated at each stage ECOG PST stage. Neither lymphocyte nor platelet count associations were independently significant.

The prognostic value of the NLR
-------------------------------

A number of previous studies have explored the NLR in patients with HCC. An NLR of ⩾5 *vs* \<5 was shown to be a poor prognostic indicator in a cohort of 96 patients undergoing resection ([@bib12]), as well as in a cohort of 160 patients treated with liver transplantation ([@bib21]). This cutoff value in fact performed poorly in our combined cohort of 152 surgically treated patients, where only 20 had an NLR ⩾5. Using a median cutoff value for our combined surgical cohort of ⩾2.5 *vs* \<2.5 (Newcastle cases 41 *vs* 43; Hong Kong cases 35 *vs* 33), there was again no significant difference in either median or long term survival between the groups. The majority of patients undergoing surgical treatment in our cohorts (87%) had HCC classed as TNM stage I or II, without an obvious difference in NLR between these stages of disease ([Figure 1](#fig1){ref-type="fig"}).

In patients with all stages of disease, however, the whole cohort median NLR value of 3.15 was a very highly significant discriminator by Kaplan--Meier analysis. Median survival in the combined cohort (*n*=578 \<3.15; *vs* *n*=588 ⩾3.15) was 18.8 months *vs* 4.5 months (*P*\<0.001, Kaplan--Meier, as shown in [Figure 4](#fig4){ref-type="fig"}). In a multivariate Cox regression analysis, including other variables significant in a univariate analysis (tumour number, largest diameter, prothrombin time, albumin, bilirubin and AFP as continuous variables; the presence of ascites, portal vein invasion, extrahepatic disease, constitutional symptoms, underlying aetiology and primary treatment group as categorical variables), an NLR ⩾3.15 was independently associated with poorer survival (hazard ratio (HR) 0.71; 0.62--0.81; *P*\<0.001).

The prognostic value of the SII
-------------------------------

Recognising the potential contribution of circulating platelets, with a particular interest in the role they play in promoting circulating tumour cell survival and metastases, [@bib17] proposed the SII index as an alternative and possibly more informative biomarker. To calculate the SII, the NLR is multiplied by the platelet count. [@bib17] used a retrospective cohort of 133 resection patients to propose an SII \>330 × 10^9^ as having poor prognostic value, which they validated in a prospective cohort of 123 patients. An SII \>300 showed promise in our small transplanted cohort (*n*=53), trending towards significance (median survival 90.8 months (*n*=31), *vs* 72.2 months (*n*=22), for SII \<300 or \>300, respectively, *P*=0.280). In our combined resection series (*n*=99), however, the trend was reversed (median survival 82.4 months (*n*=33) *vs* 125.0 months (*n*=66); *P*=0.164). For these small groups of surgically treated patients, therefore, we did not confirm a prognostic value in terms of survival. In our entire combined cohort, however, an SII \>300 was present in 847 of 1168 patients, associated with a median survival of 6.9 months compared with 21.9 months for those with an SII \<300 (*P*\<0.001, Kaplan--Meier). The survival curves comparing patients below and above the median SII of 569 (*n*=582 *vs* 584) are shown in [Figure 4](#fig4){ref-type="fig"} (18.9 months *vs* 4.4 months, *P*\<0.001). In a multivariate Cox regression analysis similar to that described for the NLR, a median SII above the median value was independently associated with poorer survival (HR 0.70; 0.60--0.81, *P*\<0.001).

In our combined cohort, both the NLR and the SII as continuous variables correlated highly significantly with tumour number, tumour size, vascular invasion, AFP and extrahepatic disease. The stronger correlations were with the SII, in particular with tumour size (0.498, Spearman's correlation, *P*\<0.001).

Exploration of the contributions of distinct inflammatory cells
---------------------------------------------------------------

In the large combined cohort studied, including all stages of disease and underlying aetiologies, we aimed to explore the independent contributions and associations of the cell types, rather than the combination scores. Focused on survival, univariate analyses for the Newcastle cohort, the Hong Kong cohort and the combined cohort, followed by multivariate Cox regression analysis including those variables with a *P*-value \<0.05, are shown in [Table 2](#tbl2){ref-type="table"}. Variables independently significantly associated with adverse survival in the Newcastle cohort, validated in the Hong Kong cohort, included tumour factors (increased HCC number or size and the presence of vascular invasion or extrahepatic disease), falling serum albumin, rising bilirubin, the presence of constitutional symptoms and a rising peripheral neutrophil count. Additional factors in the Hong Kong cohort significantly associated with adverse survival included the presence of ascites, an elevated AFP, an elevated prothrombin time, as well as a lower lymphocyte count. In the larger combined cohort, where there was no significant difference in survival between the two cohorts, independent significance persisted for serum AFP and the presence of ascites, but not for the prothrombin time or lymphocyte count. Notably, in both cohorts, the peripheral neutrophil count was the only inflammatory cell count with independent prognostic value in a multivariate Cox regression analysis including all variables with a *P*-value \<0.05. Treated as a categorical variable, taking the neutrophil median value as the cutoff discriminating two groups of patients (\<4.2 *vs* ⩾4.2), the difference in median survival was 17.3 *vs* 5.1 months (Kaplan--Meier; *P*\<0.001, [Figure 4](#fig4){ref-type="fig"}), with similarly independent significance (HR 0.77, 0.66--0.89; *P*=0.001). The survival curves for both lymphocytes and platelet counts, above and below their median values, were significant by Kaplan--Meier analyses, also shown in [Figure 4](#fig4){ref-type="fig"}. Again, neither was significant in a multivariate analysis.

Exploring neutrophil associations with the other inflammatory cells in the combined cohort, a positive and highly significant correlation was noted with platelets (0.565, *P*\<0.001). A much weaker but still significant correlation was also observed with lymphocytes (0.108, *P*\<0.001). As described, the presence or absence of cirrhosis had a significant impact on cell counts, with median values (SI units × 10^9^ l^−1^) in the absence and presence of cirrhosis being 5.0 *vs* 3.9; 246 *vs* 143; 1.6 *vs* 1.4 for neutrophils, platelets and lymphocytes, respectively (*P*\<0.001; *P*\<0.001 and *P*=0.001 respectively, Mann--Whitney). Focused only on patients without cirrhosis, the highly significant correlation between neutrophils and platelets remained (Spearman's 0.402, *P*\<0.001), whereas the weak association between neutrophils and lymphocytes was lost (Spearman 0.012, *P*=0.805). Revisiting survival, restricting analyses to patients without cirrhosis, neutrophils remained the only circulating cell significantly and independently associated with survival (data not shown).

Discussion
==========

Studying two large cohorts of patients with HCC from Newcastle and Hong Kong has provided the opportunity to explore the prognostic value of peripheral cell counts and combination scores in much greater depth than before, as previous case series have tended to be small and/or focused on specific treatment groups. Including all patients presenting to our units over defined periods of time has captured all stages of disease. Furthermore, the quite marked differences between the Newcastle and Hong Kong cohorts has facilitated a comprehensive assessment of the value of combined scores, as well as the contributions of individual cell types, which goes beyond the influence of important factors such as age, sex, underlying aetiology of disease, geographical location, presence or absence of cirrhosis and treatments received.

Circulating inflammatory cell counts and combined inflammatory scores generally increased with more advanced TNM, CP and BCLC stage, with the exception being lymphocytes, which were inversely related. Notably, lymphocyte counts were slightly lower in the Hong Kong cohort independently of stage and variance in the systemic inflammatory response associated with geographical location have been previously reported ([@bib10]). As cirrhosis with portal hypertension has a very well established impact on circulating cell counts, it was important to confirm that the associations with advancing stage persisted even in the absence of cirrhosis, supporting the influence of the advancing cancer on these peripheral cell counts. The association of neutrophils with PST was notable and persisted in a multinomial regression analysis independently of other highly significantly associated factors. This raises the possibility that elevated numbers of circulating neutrophils may contribute to the cancer related cachexia syndrome, of which declining PST is a critical part. Although not well understood, an inflammatory tumour microenvironment has a key role in the development of cancer related cachexia, with neutrophil infiltration in association with elevated levels of circulating neutrophils reported in animal studies ([@bib8]). Not only does PST have a major impact on cancer patients' survival, it also impairs the capacity to withstand the anti-cancer treatments that might prolong survival.

Turning to prognosis, in this study we have comprehensively assessed the prognostic survival value of both the NLR and the SII. Taken across all stages of disease in these large cohorts, rising values undoubtedly have prognostic value, although their clinical value within stages of disease and treatment categories remains uncertain. In our combined series of 152 surgically treated patients, where the majority in our series (87%) were TNM I or TNM II, we did not show significant differences in prognostic value for the two widely reported 'cut off' values in either NLR or SII. The sensitivity and specificity of these scores with early TNM stage disease is therefore unlikely to be robust enough to influence treatment decisions for individual patients at presentation. However, these tools may yet have clinical value directing treatments within the BCLC algorithm for those with more advanced disease. The median NLR of 3.15, for example, distinguished significant survival differences within patients classed as either BCLC B (*n*=147 *vs* 87, median survival 28.9 *vs* 15.9 months, *P*=0.013, Kaplan--Meier) or those classed as BCLC C (*n*=248 *vs* 334, median survival 9.9 *vs* 3.6 months, *P*\<0.001, Kaplan--Meier).

Considering the individual peripheral circulating cell counts and survival analyses in the Newcastle cohort, the Hong Kong cohort or the combined cohort, it was the neutrophil count that stood out as being highly significantly and independently associated with poorer survival. Notably, in the Hong Kong cohort where the lymphocyte count was slightly lower, the lymphocyte count was independently associated with poorer survival. In this distinct geographical location the predominant underlying aetiology of HCC is chronic viral hepatitis compared with ARLD or NAFLD in Newcastle. Whether this is the cause of slightly lower lymphocytes in this geographical location is uncertain, but it is interesting as the data suggests that factors other than the cancer itself that suppress the lymphocyte count may also contribute adversely to prognosis in patients with HCC. The more consistent observation in our study, however, independent of all other factors including geographical location or underlying aetiology, was the association of poorer survival with elevated neutrophils.

Neutrophils are not only the commonest white blood cells in the circulation, they also have a shorter lifespan than the other cell types. Neutrophils typically survive 5--90 h in the circulation with an additional 1--2 days outside the circulation, compared with a week or so for lymphocytes and 8--9 days for platelets. Thus, we considered the possibility that these significant associations of neutrophils were enhanced relative to other cells, owing to a lesser impact of portal hypertension and hypersplenism - but the persistence of significance in the absence of CLD was against this. Neutrophils are the 'first responders' to insult or injury and it is likely that they are one of the first immune cells to come into contact with tumour cells. Our recent work in an animal model of DEN-induced HCC highlights a potential role in promoting cancer growth, as neutrophil depletion in advanced stage disease reduced tumour burden ([@bib35]). Associated mechanisms are unclear, but neutrophils are part of the spectrum of myeloid suppressor cells (MDSCs), recognised as key regulators of the tumour microenvironment, including the infiltration and phenotype of lymphocytes. The present study is on circulating cells rather than the cells in the tumour microenvironment, and how circulating neutrophil numbers reflect the tumour microenvironment is unknown. Similarly, the contribution of MDSCs to the circulating 'neutrophil' population is also unknown. In the circulation there was no apparent relationship between neutrophils and lymphocytes in the absence of CLD, although lymphocyte subtypes were not assessed. It was notable that there was a highly significant association between neutrophils and platelets in the circulation. Similar correlations between the two, with prognostic value, have been reported in other settings ([@bib31]; [@bib33]). More commonly reported is the role of platelets in activating neutrophils. Immune and inflammatory responses require neutrophils to migrate through endothelial vasculature -- a process dependent on their prior interaction with activated platelets ([@bib29]). In the circulation, platelets also contribute to the creation of neutrophil extracellular traps, which serve to ensnare and kill pathogens, but can inflict significant tissue damage ([@bib19]). In the cancer setting, similar interactions with circulating tumour cells may have roles in their elimination or metastatic implantation ([@bib25]).

In summary, by studying two consecutive series of patients totalling 1168, we have been able to validate the prognostic role of both the NLR and SII in patients with more advanced stages of HCC. Considering the individual cell types and their associations with advanced disease, we have identified that circulating neutrophils -- rather than lymphocytes or platelets -- are significantly and independently associated with poorer prognosis and speculate that neutrophils have roles in promoting immune mediated tumour progression as well as the cancer cachexia syndrome. The relationship between circulating neutrophils -- either counts or subtypes -- with the tumour microenvironment has yet to be established. However, we propose that neutrophil phenotype and function, including interactions or regulatory roles with platelets or lymphocytes in the presence of cancer, are worthy of study and consideration as clinically relevant therapeutic targets.
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![**Inflammatory cells associations with TNM stage.** Newcastle and Hong Kong data sets combined associations with advancing tumour node metastasis (TNM) stage for neutrophil, platelets and lymphocytes, as well as NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-Inflammation Index) are shown. Statistical differences were assessed by Kruskal--Wallis test.](bjc2017386f1){#fig1}

![**Inflammatory cells associations with CP stage.** Newcastle and Hong Kong data sets combined associations with advancing Childs-Pugh (CP) stage for neutrophil, platelets and lymphocytes, as well as NLR (neutrophil to lymphocyte ratio) and SII (systemic immune index) are shown. Statistical differences were assessed by Kruskal--Wallis test.](bjc2017386f2){#fig2}

![**Inflammatory cells associations with PST.** Newcastle and Hong Kong data sets combined associations with advancing Eastern Cooperative Oncology Group (ECOG) performance status (PST) for neutrophil, platelets and lymphocytes, as well as NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-Inflammation Index) are shown. Statistical differences were assessed by Kruskal--Wallis test.](bjc2017386f3){#fig3}

![**Inflammatory cells associations with survival.** Newcastle and Hong Kong data sets combined Kaplan--Meier survival curves for neutrophils, platelets and lymphocytes, as well as NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-Inflammation Index) are shown (**A**--**E**). In each case, two similar size groups were created based on the median value of the variable in the combined cohort. The mean value is shown on each plot, with median survival in months for those above and below the median shown in brackets. The *P*-value shown is that of the Kaplan--Meier comparisons. Univariate and multivariate Cox Regression analyses are shown in [Table 2](#tbl2){ref-type="table"}.](bjc2017386f4){#fig4}

###### Patient cohorts

                                              **Newcastle cohort 01 January 2000--31 December 2010**   **Hong Kong cohort 01 January 2007--31 July 2013**   ***P*-value**   **Combined cohort**
  ------------------------------------------ -------------------------------------------------------- ---------------------------------------------------- --------------- ---------------------
  Demographics                                                                                                                                                                        
   Sample size                                                         583                                                    585                                                  1168
   Age (median) (range)                                            69 (18--93)                                            60 (18--88)                          \<0.001          65 (18--93)
   Male/female (%)                                             473/110 (81.1/18.9)                                     516/69 (88.2/11.8)                       0.008       989/179(84.7/15.3)
  Tumour characteristics                                                                                                                                                              
   Tumour number (median)                                               1                                                      2                                0.790                2
   Tumour size (cm, median)                                            4.5                                                    7.8                              \<0.001               6
   Extrahepatic disease N/Y                                           489/94                                                452/133                             0.004             820/348
   Vascular invasion N/Y                                             430/153                                                390/195                             0.008             941/227
   Cirrhosis N/Y (%)                                           157/426 (26.9/73.1)                                    246/339 (42.1/57.9)                      \<0.001      403/765 (34.5/65.5)
  Aetiology of liver disease (% of cohort)                                                                                                                                            
   ALD                                                              168 (28.8)                                                 0                               \<0.001          168 (14.4)
   NAFLD                                                            127 (21.8)                                                 0                                                127 (10.9)
   HBV                                                               28 (4.8)                                              469 (80.2)                                           497 (42.5)
   HCV                                                              60 (10.3)                                               41 (7.1)                                             101 (8.7)
   Haemachromatosis                                                  31 (5.3)                                                  0                                                 31 (2.6)
   AIH/PBC/PSC                                                       27 (4.6)                                                  0                                                 27 (2.3)
   Cryptogenic/other cirrhosis                                       28 (4.8)                                               36 (6.1)                                             64 (5.5)
   No underlying CLD                                                114 (19.6)                                              39 (6.6)                                            153 (13.1)
  ECOG PS                                                                                                                                                                             
   ECOG PS 0                                                           217                                                    186                              \<0.001              403
   ECOG PS 1                                                           160                                                    365                                                   525
   ECOG PS 2                                                           115                                                     25                                                   140
   ECOG PS 3                                                            78                                                     9                                                    87
   ECOG PS 4                                                            13                                                     0                                                    13
  TNM                                                                                                                                                                                 
   TNM I                                                               214                                                     24                               0.001               238
   TNM II                                                              106                                                    140                                                   246
   TNM IIIA or IIIB                                                    168                                                     82                                                   250
   TNM IV                                                               95                                                    339                                                   434
  Childs--Pugh                                                                                                                                                                        
   Childs--Pugh A                                                      370                                                    402                              \<0.001              772
   Childs--Pugh B                                                      133                                                    156                                                   289
   Childs--Pugh C                                                       80                                                     27                                                   107
  BCLC stage                                                                                                                                                                          
   BCLC stage 0/A                                                       88                                                     94                              \<0.001              182
   BCLC stage B                                                         94                                                    140                                                   234
   BCLC stage C                                                        268                                                    316                                                   584
   BCLC stage D                                                        133                                                     35                                                   168
  Peripheral cell counts                                                                                                                                                              
   Neutrophils (mean±s.e.)                                           4.8±0.1                                                4.9±0.1                             0.129             4.9±0.1
   Lymphocytes (mean±s.e.)                                           1.5±0.0                                                1.3±0.0                            \<0.001            1.4±0.0
   Platelets (mean±s.e.)                                             199±5.3                                                206±5.5                             0.240             203±3.8
   NLR (mean±s.e.)                                                   4.1±0.2                                                4.9±0.2                            \<0.001            4.5±0.1
   SII (mean±s.e.)                                                    857±46                                                1113±63                            \<0.001            986±40
  Primary treatment                                                                                                                                                                   
   Liver transplant                                                     53                                                     0                               \<0.001              53
   Resection                                                            31                                                     68                                                   99
   Locoregional                                                        253                                                    168                                                   421
   Sorafenib                                                            9                                                     128                                                   137
   Supportive care                                                     237                                                    221                                                   458
  Median survival (months)                                      11.9 (10.2--13.6)                                       8.4 (6.8--10.1)                         0.219         10 (8.7--11.3)

Abbreviations: AIH=autoimmune hepatitis; ARLD=alcohol-related liver disease; BCLC=Barcelona Clinic for Liver Cancer; CLD=chronic liver disease; ECOG = Eastern Cooperative Oncology Group; HBV=hepatitis B virus; HCV=hepatitis C virus; NAFLD=non-alcoholic fatty liver disease; NLR=neutrophil lymphocyte ratio; N/Y=no/yes; PBC=primary biliary cholangitis; PS=performance status; PSC=primary sclerosing cholangitis; SII=Systemic Immune-Inflammation Index.

The patient demographic data, disease aetiology, tumour characteristics, liver function parameters, functional status and treatments administered are summarised for both Newcastle and Hong Kong Cohorts discretely, as well as for the combined cohort. Differences between the two data sets were determined by Chi Square for categorical data, or Mann-Whitney test for continuous data. Cell count data are shown as a mean value representing × 10^9^ l^−1^.

###### Predictors of survival: univariate and multivariate survival analyses

                           **Newcastle cohort**   **Hong Kong cohort**   **Combined Cohort**                                                                                  
  ------------------------ ---------------------- ---------------------- --------------------- ------------ --------- --------- ------ ----------- --------- --------- ------ -----------
  Age                      \<0.001                \<0.001                1.02                   1.01--1.03  0.737                                  0.016     \<0.001   1.02   1.01-1.03
  Sex                      0.595                                                                            0.173                                  0.513                       
  Aetiology                0.143                                                                            0.144                                  0.639                       
  Absence cirrhosis        0.730                                                                            0.341                                  0.498                       
  Cohort                   NA                                                                               NA                                     0.219                       
  No of tumours            \<0.001                \<0.001                1.07                   1.04--1.11  \<0.001   \<0.001   2.00   1.63-2.46   \<0.001   0.001     1.07   1.04-1.11
  Size of largest (cm)     \<0.001                \<0.001                1.06                   1.03--1.08  \<0.001   \<0.001   1.06   1.04-1.09   \<0.001   \<0.001   1.06   1.04-1.08
  Absence VI               \<0.001                0.001                  0.48                   0.38--0.60  \<0.001   \<0.001   0.47   0.38-0.58   \<0.001   \<0.001   0.45   0.38-.52
  Absence EHD              \<0.001                0.042                  0.60                   0.45--0.79  \<0.001   0.011     0.74   0.58-0.94   \<0.001   \<0.001   0.56   0.47-0.67
  Absence ascites          \<0.001                0.225                                                     \<0.001   0.007     0.74   0.58-0.93   \<0.001   0.017     0.81   0.69-0.96
  AFP (median)             0.033                  0.389                                                     \<0.001   \<0.001   1.00   1.00-1.00   \<0.001   \<0.001   1.00   1.00-1.00
  Albumin (g l^−1^)        \<0.001                \<0.001                0.96                   0.94--0.97  \<0.001   0.009     0.97   0.96-0.99   \<0.001   \<0.001   0.96   0.95-0.98
  Bilirubin (μmol l^−1^)   \<0.001                0.027                  1.00                   1.00--1.01  \<0.001   \<0.001   1.00   1.00-1.01   \<0.001   0.001     1.00   1.00-1.00
  Prothrombin time         0.161                                                                            \<0.001   0.032     1.06   1.01-1.12   0.002     0.294             
  Absence symptoms         \<0.001                \<0.001                0.46                   0.38--0.58  \<0.001   0.026     0.76   0.60-0.97   \<0.001   \<0.001   0.61   0.53-0.71
  Neutrophils              \<0.001                0.013                  1.05                   1.01--1.10  \<0.001   \<0.001   1.11   1.06-1.15   \<0.001   \<0.001   1.08   1.05-1.11
  Lymphocytes              0.166                                                                            \<0.001   0.021     0.83   0.71-0.97   \<0.001   0.102             
  Platelets                \<0.001                0.666                                                     \<0.001   0.172                        \<0.001   0.811             

Abbreviations: AFP=*α*-fetoprotein; CI=confidence intervals; EHD=extrahepatic disease; HR=hazard ratio; NA=not applicable; VI=vascular invasion.

In the multivariate cox regression analysis, variables with a *P*-value \<0.05 on univariate analysis were included. Significance and HR with upper and lower 95% CIs are shown. Variables included VI and EHD.

The univariate analyses for survival associations for each of the Newcastle, Hong Kong and Combined Cohorts are shown, followed by multivariate analyses including variables with univariate *P*-values \<0.05. Those variables independently significant in Newcastle, Hong Kong and Combined Cohorts are highlighted in grey. Significance and HR with upper and lower 95% CIs are shown. Variables included VI and EHD.

[^1]: These authors contributed equally to this work.
